Devraj Basu, MD, PhD, FACS
@BasuLab1
Cancer surgeon-scientist @PennMedicine. Our lab advances therapy for #headandneckcancer #HPV #hnscm. Opinions my own. Patient appointments 2156626972
You might like
@JNCI_Now We defined the gene expression profiles distinguishing HPV+ OPSCCs that are prone to recur after TORS-based therapy. These the tumor-intrinsic and immune-related traits were tightly interrelated and generalizeable to nonsurgical cases as well. academic.oup.com/jnci/advance-a…
The field is understandably desperate to improve outcomes in this high-risk population of HPV-negative HNSCC. However, we also have to be cautious in interpreting phase II studies. This sub-100 patient trial led to a truly immense amount of additional work (and money) that…
The optimal management of oligometastatic HNSCC is a debated and important question. How can we improve *overall survival* in this more favorable population? EA3211 is a phase III randomized trial studying this exact issue. Enrollment is even more streamlined with the most…
#ClinicalTrial EA3211, led by @DavidSherMD of @utswcancer, aims to improve results for patients with #HeadAndNeckCancer that has spread to a limited number of places. Learn more: bit.ly/ea3211-study
K-means is one of the most powerful algorithms for data scientists. But it's confusing for beginners. Let's fix that:
I think we need to reserve judgement and final analysis until seeing all of the papers from these trials…. … but are these results really so different? - In the US trial, more IMRT patients (40% vs. 27% = 13% difference) received g-tubes. - In the UK trial, more IMRT patients…
A hopeful NCI director choice for cancer patients and those committed to advancing cancer care. Godspeed to Dr. Letai in navigating the challenges of his new role. science.org/content/articl…
Interesting work on how anti-tumor immune suppression and anti-PD1 resistance arises via PNI and strategies to reverse it nature.com/articles/s4158…
It was such a pleasure to read the results of this juicy and terrific randomized trial of postop RT dose de-escalation for HPV+ OPSCC from @DanielMaMD and colleagues at @MayoRadOnc. The field has been waiting for the formal results, and this paper does not disappoint.…
This paper is a nice addition to the literature on the successful use of carboplatin-paclitaxel as a radiation sensitizer. The favorable results clearly motivate larger prospective trials on the use of carbo-pac as a radiation sensitizer in HNSCC. The most commonly delivered…
In patients with SCCHN receiving radiation with C/P vs cisplatin, there were no differences in locoregional recurrence-free survival, progression-free survival, distant metastasis-free survival, and overall survival. ja.ma/47t0I24 @DRNabilSaba @NikkiSchmittMD
Xevinapant or Placebo Plus Platinum-Based Chemoradiotherapy in Unresected Locally Advanced Squamous Cell Carcinoma of the Head and Neck (TrilynX): A Randomized, Phase III Study | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JC…
Long-Term Follow-Up of E3311, an ECOG-ACRIN Cancer Research Group Phase II Trial of Transoral Surgery and Risk-Based Adjuvant Treatment in Human Papillomavirus–Initiated Oropharynx Cancer | Journal of Clinical Oncology ascopubs.org/doi/full/10.12…
T cells do the heavy lifting when it comes to the anti-tumor action of checkpoint immunotherapy. But do antibodies play a role too? That’s the question @yile_dai looked to answer in his thesis work, out today in @Nature! 🧵below nature.com/articles/s4158…
A @PennCancer team has defined a network of tumor-intrinsic and immune-related molecular traits that distinguish the subset of early stage HPV+ oropharyngeal cancers predisposed to fail standard therapy:oxford.ly/45wkbOu @basulab1 @PennMedicine @Penn_ENT @Penn_CBIO.
I’ve been urged by colleagues to broadcast this loudly @NIHDirector_Jay @RobertKennedyJr 🎤 🇺🇸 📣 📢 ☎️
FDA approves pembrolizumab for resectable, locally advanced HNSCC based on KEYNOTE‑689. Led by Dr. Ravindra Uppaluri @DrUppaluri, the study showed a 30% drop in recurrence risk. Full details from The ASCO Post: ascopost.com/news/june-2025… #HNSCC #Oncology
Work with Sagar Kansara, MD, @lucmorrisnyc, @AHNS to help starting to assess how best to apply neoadjuvant + adjuvant anti-PD1 to advanced resectable head and neck cancer in standard clinical practice
An infographic presented by the AHNS Basic and Translational Science Service The promise and uncertainties of applying the new neoadjuvant anti-PD1 standard created by KEYNOTE-689 #AHNS #neoadjuvant #immunotherapy #HNSCC
In case anyone else is also having trouble keeping track...
I'd say ctDNA assays in general. A lot of different assays/variations in sensitivity. I made a very rough table and am going to update it later.
United States Trends
- 1. #BaddiesUSA 50.7K posts
- 2. Rams 27.8K posts
- 3. Cowboys 97.1K posts
- 4. Eagles 137K posts
- 5. Scotty 8,849 posts
- 6. #TROLLBOY 1,722 posts
- 7. Chip Kelly 7,822 posts
- 8. Stafford 13.7K posts
- 9. Bucs 12K posts
- 10. Baker 20.5K posts
- 11. Raiders 65.1K posts
- 12. #RHOP 10.6K posts
- 13. Stacey 29.4K posts
- 14. #ITWelcomeToDerry 13.2K posts
- 15. Teddy Bridgewater 1,154 posts
- 16. Todd Bowles 1,932 posts
- 17. Ahna 5,967 posts
- 18. DOGE 157K posts
- 19. Lemmy 4,378 posts
- 20. Vin Diesel N/A
You might like
-
Robert Ferris, MD, PhD
@RobertFerrisMD -
AHNS
@AHNSinfo -
Umamaheswar Duvvuri MD PhD
@duvvuri_md -
Robert Haddad
@DrHaddadRobert -
Dr Greg Farwell
@DrGregFarwell -
José P. Zevallos, MD, MPH, FACS
@jpzevallos -
Eben L Rosenthal, MD
@EbenRosenthal -
John De Almeida
@DrJohndeAlmeida -
Heath Skinner, MD PhD
@HSkinnerMDPhD -
Neil D. Gross, MD, FACS
@DrNeilGross -
Karthik Rajasekaran
@RajasekaranMD -
Nabil Saba, MD
@DrNabilSaba -
Penn Otorhinolaryngology
@Penn_ENT -
Ravi Uppaluri, MDPhD
@DrUppaluri -
Michael Topf MD, MSCI
@TopfHNS
Something went wrong.
Something went wrong.